Monitor the special meeting vote and regulatory clearances (HSR waiting period expires June 18, 2026; Indian FEMA approval filed June 15, 2026). The disinterested stockholder vote is the key binary risk — the Amneal Group owns ~44% of shares and cannot vote on the transaction proposal, so approval depends on retail and institutional holders. If approved, the deal transforms Amneal's biosimilars platform and could drive significant revenue growth by 2028-2030 as Kashiv's pipeline launches.
Price Chart
Executive Summary
Amneal Pharmaceuticals is seeking shareholder approval to acquire Kashiv BioSciences, a vertically integrated biosimilars company, for $375M in cash (subject to adjustments) plus 28.9M shares of AMRX Class A common stock, with up to $350M in additional contingent milestone payments and 12-year royalty payments. The transaction is a related-party deal (Amneal's co-CEOs and other directors have interests in Kashiv) and was negotiated by an independent committee with a fairness opinion from Goldman Sachs. The deal requires approval from disinterested stockholders and is expected to close in H2 2026, subject to HSR clearance, Indian regulatory approvals, and other conditions.
Key Financial Metrics
Key Facts
- Amneal to acquire 100% of Kashiv for $375M cash (subject to adjustments) plus 28,942,108 shares of AMRX Class A common stock
- Sellers eligible for up to $350M in contingent milestone payments and 12-year royalty payments equal to 25% of gross profits above specified hurdles
- Goldman Sachs delivered fairness opinion that consideration is fair from a financial point of view to Amneal
- Independent Committee of disinterested directors unanimously approved and recommends the transaction
- Transaction requires approval by majority of votes cast by disinterested stockholders and majority of votes cast by all stockholders for stock issuance
- Expected to close in second half of 2026; conditions include HSR clearance, Indian regulatory approvals, and Nasdaq listing
- Amneal's obligation to consummate is not subject to any financing condition; expects to fund cash portion with $350M incremental debt
- Kashiv has more than 600 employees, two FDA-approved biosimilars (Releuko, Fylnetra), and a pipeline of over 20 biosimilar candidates
Financial Impact
Total preliminary estimated aggregate consideration of approximately $1.237B, including $277.5M net cash at closing, $449.3M in equity (28.9M shares at $16.34 with 5% DLOM), $117.2M fair value of milestone payments, $203.1M fair value of royalty payments, and $162.4M for debt payoff. Pro forma combined net revenue of $3.034B for FY2025.
Risk Factors
- Failure to obtain disinterested stockholder approval (majority of votes cast required)
- HSR or Indian regulatory delays or conditions
- Integration risk and execution of Kashiv's pipeline (multiple biosimilar candidates in development)
- Related-party conflicts and potential litigation
- Dilution of ~9% from stock issuance; additional dilution if contingent milestones achieved
- Kashiv has going-concern uncertainty and negative cash flow; requires Amneal funding post-close
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREM14A Filing (Primary) | 0001140361-26-025784 |
| Document: ny20075452x1_ex107.htm | 0001140361-26-025784 |
| Document: 0001140361-26-025784-index-headers.html | 0001140361-26-025784 |
| Document: 0001140361-26-025784-index.html | 0001140361-26-025784 |
| Document: 0001140361-26-025784.txt | 0001140361-26-025784 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K/A | $20.38 | awaiting T+60 | — | $21.44 (+5.20%) |
Sep 18, 2026 5w ago | Press Release | $20.16 | awaiting T+60 | — | $21.44 (+6.35%) |
Aug 16, 2026 10w ago | Institutional Cluster | $18.42 | awaiting T+60 | — | $21.44 (+16.40%) |
Aug 14, 2026 10w ago | Insider Cluster | $18.42 | awaiting T+60 | — | $21.44 (+16.40%) |
Aug 13, 2026 10w ago | Insider Cluster | $18.15 | awaiting T+60 | — | $21.44 (−18.13%) |
Aug 10, 2026 11w ago | 8-K | $17.10 | awaiting T+60 | — | $21.44 (+25.38%) |
Jul 30, 2026 12w ago | DEFA14A | $18.50 $20.38 | ▲ +10.16% | ▲ +7.70% | $21.44 (+15.89%) |
Jul 17, 2026 14w ago | Press Release | $17.85 $20.03 | ▲ +12.21% | ▲ +7.53% | $21.44 (+20.11%) |
Jun 29, 2026 17w ago | DEFM14A | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.44 (+24.00%) |
Jun 29, 2026 17w ago | Press Release | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.44 (+24.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers